Establishment Labs (NASDAQ:ESTA) Price Target Raised to $103.00

Establishment Labs (NASDAQ:ESTA) had its target price lifted by BTIG Research from $96.00 to $103.00 in a research note published on Thursday morning, MarketBeat Ratings reports. BTIG Research currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on ESTA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Mizuho raised their target price on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Needham & Company LLC boosted their price target on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday. TD Cowen increased their price objective on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, Citigroup increased their price objective on shares of Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average price target of $100.25.

Establishment Labs Trading Down 2.1%

Shares of ESTA stock opened at $77.42 on Thursday. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -59.10 and a beta of 1.07. Establishment Labs has a 12-month low of $33.35 and a 12-month high of $97.59. The stock’s 50-day moving average price is $86.43 and its 200-day moving average price is $74.25.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 205.79%. Establishment Labs’s quarterly revenue was up 31.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.57) earnings per share. Equities research analysts predict that Establishment Labs will post -1.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Several institutional investors have recently modified their holdings of ESTA. KBC Group NV purchased a new position in shares of Establishment Labs in the 1st quarter worth approximately $28,000. Quarry LP purchased a new stake in Establishment Labs during the 3rd quarter valued at $34,000. Kestra Advisory Services LLC bought a new stake in Establishment Labs in the fourth quarter worth $47,000. Osaic Holdings Inc. lifted its position in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the last quarter. Finally, State of Wyoming bought a new stake in Establishment Labs in the second quarter worth $87,000. 72.91% of the stock is owned by institutional investors.

Establishment Labs News Summary

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Establishment Labs from $84 to $95 and maintained an Overweight rating, implying substantial upside from the current trading level. Benzinga analyst report
• Positive Sentiment: BTIG increased its price target from $96 to $103 and reiterated a Buy rating, while Needham lifted its target from $86 to $95 and also maintained a Buy rating. These revisions suggest analysts remain optimistic about the company’s growth prospects. The Fly analyst report
• Positive Sentiment: Establishment Labs reported quarterly revenue of $67.54 million, exceeding the $65.79 million analyst estimate and increasing 31.7% year over year. The company also projected 2026 revenue of $269 million to $271 million, above the $267.5 million consensus estimate. Zacks quarterly results report
• Neutral Sentiment: Management indicated that minimally invasive procedures now account for approximately 15% of sales, highlighting potential for longer-term market expansion, but investors may remain focused on the company’s path to profitability. Seeking Alpha revenue outlook report
• Negative Sentiment: The company reported a second-quarter loss of $0.39 per share, wider than the $0.34 expected loss, though the result improved from a $0.57 loss in the year-ago quarter. The earnings miss, continued negative margins, and lack of profitability are likely weighing on the shares. MarketBeat earnings report

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.